Dr Saima Ubaid Khawaja, MD | |
2316 E Meyer Blvd, Kansas City, MO 64132-1136 | |
(816) 276-4360 | |
(816) 795-8171 |
Full Name | Dr Saima Ubaid Khawaja |
---|---|
Gender | Female |
Speciality | Hospitalist |
Location | 2316 E Meyer Blvd, Kansas City, Missouri |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1891768172 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 2011005776 (Missouri) | Primary |
207R00000X | Internal Medicine | 2011005776 (Missouri) | Secondary |
Entity Name | Dhew Ind Hlth Sv Hlth Svs & Mntl Hlth Adm |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1083643738 PECOS PAC ID: 1759290901 Enrollment ID: O20031105000797 |
News Archive
Politico reports that other steps in the online enrollment process, including computing subsidies and transferring signup information to insurers may also have bugs. The Associated Press reports that some insiders predicted the problems well before the website launch, while The Washington Post notes that paper applications are increasingly popular because of the problems.
Vitamin D-deficient individuals are twice as likely to be diagnosed with schizophrenia as people who have sufficient levels of the vitamin, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Insurance rates may rise next year even more than anticipated because of the health overhaul for mid-sized companies. "While most major pieces of the new health law don't go into effect until 2014, some reforms affecting health insurance carriers take effect this year. These include provisions that require health plans to cover adult children until age 26, extend coverage to children with pre-existing conditions, end maximum lifetime spending limits and end the practice of retroactively canceling a member's coverage for any reason other than fraud."
AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
› Verified 7 days ago
Entity Name | Ea Health Physicians Medical Group Texas Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1063786523 PECOS PAC ID: 2769645563 Enrollment ID: O20120515000031 |
News Archive
Politico reports that other steps in the online enrollment process, including computing subsidies and transferring signup information to insurers may also have bugs. The Associated Press reports that some insiders predicted the problems well before the website launch, while The Washington Post notes that paper applications are increasingly popular because of the problems.
Vitamin D-deficient individuals are twice as likely to be diagnosed with schizophrenia as people who have sufficient levels of the vitamin, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Insurance rates may rise next year even more than anticipated because of the health overhaul for mid-sized companies. "While most major pieces of the new health law don't go into effect until 2014, some reforms affecting health insurance carriers take effect this year. These include provisions that require health plans to cover adult children until age 26, extend coverage to children with pre-existing conditions, end maximum lifetime spending limits and end the practice of retroactively canceling a member's coverage for any reason other than fraud."
AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Saima Ubaid Khawaja, MD 2316 E Meyer Blvd, Kansas City, MO 64132-1136 Ph: (816) 276-4360 | Dr Saima Ubaid Khawaja, MD 2316 E Meyer Blvd, Kansas City, MO 64132-1136 Ph: (816) 276-4360 |
News Archive
Politico reports that other steps in the online enrollment process, including computing subsidies and transferring signup information to insurers may also have bugs. The Associated Press reports that some insiders predicted the problems well before the website launch, while The Washington Post notes that paper applications are increasingly popular because of the problems.
Vitamin D-deficient individuals are twice as likely to be diagnosed with schizophrenia as people who have sufficient levels of the vitamin, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Insurance rates may rise next year even more than anticipated because of the health overhaul for mid-sized companies. "While most major pieces of the new health law don't go into effect until 2014, some reforms affecting health insurance carriers take effect this year. These include provisions that require health plans to cover adult children until age 26, extend coverage to children with pre-existing conditions, end maximum lifetime spending limits and end the practice of retroactively canceling a member's coverage for any reason other than fraud."
AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
› Verified 7 days ago
Subashis Paul, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 2301 Main St, Kansas City, MO 64108 Phone: 816-395-3558 | |
Tyler Porter, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 | |
Christine M. Sankpill, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Anuhya Caipa Young, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
David A Wooldridge, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Peter Lebourveau, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
David C Hermanns, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2301 Holmes St, Kansas City, MO 64108 Phone: 816-404-1000 |